Virtual reality for medical devices; China updates its medical device regulations;

@FierceMedDev: ICYMI: Volcano guides lower but offers long-term vision, Wall Street trims by as much as 25%. Article | Follow @FierceMedDev

@StacyALawrence: Med tech M&A gets much, much bigger during the first half. Feature | Follow @StacyALawrence

@VarunSaxena2: RT @foodanddruglaw: CMS delays launch of Sunshine Act reporting website. More from The Hill | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Not for the faint of heart: A behind-the-scenes look at creating prosthetic eyes. More from NPR | Follow @EmilyWFierce

> Consumers can look forward to leaps in practical virtual reality technology use, from medical devices to everyday use, particularly now that Facebook ($FB) has bought up VR company Oculus Rift. Story

> China's Food and Drug Administration has updated its medical device regulations. More

> Baby monitors have gotten an upgrade from grainy video screens to wearable anklet bracelets with sensors synced up to the parents' smartphone via an app. More (sub. req.)

> Beam Technologies raised $5 million in a venture funding round for its tooth brush and smart phone app combination. Story

Biotech News

@FierceBiotech: Can GlaxoSmithKline go from 0 to 150 on an Ebola vaccine program? Story | Follow @FierceBiotech

@JohnCFierce: ICYMI last week: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. More | Follow @JohnCFierce

@DamianFierce: $MNKD finally gets its Afrezza deal as $SNY signs up for $150M up front and $775M in milestones. Article | Follow @DamianFierce

> Forward Pharma sets sights on Biogen with a $200M IPO. Article

> J&J's diabetes combo wins FDA nod in a fast-crowding space. News

> Google sheds glancing light on Calico, its anti-aging biotech. More

Pharma News

@FiercePharma: Top-read on FP this weekend: Pfizer faces growing legal threat over Lipitor. Article | Follow @FiercePharma

@EricPFierce: ICYMI last week: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: Favorite fact I've learned so far today: The inhaler for MannKind's Afrezza inhaler is named "Dreamboat." | Follow @CarlyHFierce

> New use for Bayer's Eylea in EU gives it more market power against Novartis' Lucentis. Article

> Weber intends to build Takeda into a global player but stay true to its Japanese heritage. Story

> Former top Sanofi exec Whitaker nabbed by Synta to shuttle cancer drug to market. Report

CRO News

> Icon charts another sales jump with eyes on a big year. Report

> Charles River's checkbook fuels a leap in revenue. More

> Quintiles and Roche take to China with testing partnership. News

> Parexel notches double-digit annual growth with a big year ahead. Article

> Deal-minded Venn buys another CRO. Story

Biotech IT News

> Actelion working with PatientsLikeMe rare cancer community on outcome measure. Report

> U.S. research institutes target standard neuroscience data format. More

> AllSeq, DNAnexus share data from Illumina HiSeq X Ten. Story

> Google rolls out preview of healthcare app development kit. Article

> The race to build a robo-chemist. Item

Animal Health News

> Cost spike of doxycycline has created sticker shock for pet owners. Report

> Zoetis CEO sees global factors coalescing to spur more growth. More

> Medical marijuana coming to the pet med market. Item

> SmartPak acquisition helps Henry Schein grow its animal health sales. Story

> Zoetis expects to have PEDv vaccine ready this year. Article

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.